The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

MPN Advances Day 2019 | Ropeginterferon alfa-2b for polycythemia vera: impacts and considerations

Name: Ropeginterferon alfa-2b for polycythemia vera: impacts and considerations
Uploaded: 2019-11-15T00:00:00.000Z
Duration: 1 min 29 s
Description: From the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital, University of Paris, Paris, France, discusses the impacts of ropeginterferon alfa-2b treatment for polycythemia vera (PV). He also highlights the consideration that this treatment is not suitable for everyone.

Jean-Jacques Kiladjian • 15 Nov 2019

MPN Advances Day 2019

Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Ropeginterferon alfa-2b

From the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital, University of Paris, Paris, France, discusses the impacts of ropeginterferon alfa-2b treatment for polycythemia vera (PV). He also highlights the consideration that this treatment is not suitable for everyone.